Bicara Therapeutics Inc.
BCAX
$9.32
-$0.11-1.17%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 462.07M | 489.71M | 520.76M | 203.86M | 230.44M |
Total Receivables | -- | -- | -- | -- | -- |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | 8.69M | 12.82M | 756.00K | 2.22M | -- |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | -- | -- | -- | -- | -- |
Total Current Assets | 470.75M | 502.53M | 521.51M | 206.08M | -- |
|
|||||
Total Current Assets | 470.75M | 502.53M | 521.51M | 206.08M | -- |
Net Property, Plant & Equipment | 688.00K | 845.00K | 544.00K | 619.00K | -- |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | 6.64M | 6.62M | 2.12M | 2.09M | -- |
Total Assets | 478.08M | 510.00M | 524.17M | 208.78M | -- |
|
|||||
Total Accounts Payable | 2.74M | 4.51M | 1.96M | 4.68M | -- |
Total Accrued Expenses | 15.79M | 12.88M | 12.21M | 11.08M | -- |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | 591.00K | 607.00K | 308.00K | 300.00K | -- |
Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
Total Other Current Liabilities | -- | -- | -- | -- | -- |
Total Current Liabilities | 19.12M | 17.99M | 14.48M | 16.07M | -- |
|
|||||
Total Current Liabilities | 19.12M | 17.99M | 14.48M | 16.07M | -- |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | -- | 131.00K | 137.00K | 217.00K | -- |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | -- | -- | -- | -- | -- |
Total Liabilities | 19.12M | 18.12M | 14.62M | 16.28M | -- |
|
|||||
Common Stock & APIC | 716.82M | 712.89M | 709.61M | 7.80M | -- |
Retained Earnings | -257.86M | -221.02M | -200.06M | -182.58M | -- |
Treasury Stock & Other | -- | -- | -- | -- | -- |
Total Common Equity | 458.96M | 491.88M | 509.56M | -174.78M | -148.77M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | 367.28M | -- |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | 367.28M | 367.28M |
|
|||||
Total Common Equity | 458.96M | 491.88M | 509.56M | -174.78M | -148.77M |
Total Preferred Equity | -- | -- | -- | 367.28M | 367.28M |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 458.96M | 491.88M | 509.56M | 192.50M | 218.51M |
|